CAR T Cells in Mesothelin-Expressing Breast Cancer

Breast Cancer Clinical Trial

Official title:

Phase 1, Adaptive-design Trial of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05623488
• Other study ID #: UPCC# 15122, IRB # 852205
• Status: Recruiting
• Phase: Phase 1
• Start date: February 6, 2023
• Est. completion date: February 2038

Study information

• Verified date: January 2024
• Source: University of Pennsylvania
• Contact: Abramson Cancer Center Clinical Trials Service
• Phone: 855-216-0098
• Email: PennCancerTrials[@]careboxhealth.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase 1 - Safety and Proof of Concept

Description:

This is a phase I study to establish the safety and feasibility of lentiviral transduced CAR T cell products in patients with mesothelin expressing breast cancer. This study will be initiated as a single cohort, however the study is designed to allow for additional disease indications and other investigational CAR T cell products to be explored as separate cohorts under this protocol in the future. Cohort 1: Cohort 1 will evaluate the use of huCART-meso cells delivered intratumorally in patients with locally advanced unresectable or metastatic triple-negative breast cancer (TNBC) which is positive for mesothelin expression by IHC. Eligible subjects must also have an accessible lesion that can be targeted for both intratumoral injection and surgical excision/biopsy by either a surgeon or interventional radiology.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: February 2038
• Est. primary completion date: February 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with locally advanced unresectable or metastatic triple-negative breast

cancer as confirmed by all of the following:

1. ER-negative or low-ER positive (= 10% by IHC)

2. PR-negative or low-PR positive (= 10% by IHC)

3. HER2 negative by IHC/FISH

2. Patients with an accessible lesion that can be targeted for both intratumoral injection and surgical excision/biopsy by either a surgeon or interventional radiology.

3. Confirmed tumor mesothelin expression by = 10% of malignant cells by IHC.

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

5. Adequate organ and bone marrow function defined as:

1. Bilirubin = 2.0 x ULN

2. Serum Creatinine = 1.5 x ULN

3. ALT/AST = 3 x ULN

4. Must have a minimum level of pulmonary reserve defined as = Grade 1 dyspnea and pulse oxygen > 92% on room air

5. Left Ventricle Ejection Fraction (LVEF) = 45% confirmed by echocardiogram

6. Male and female patients = 18 years of age.

7. Provides written informed consent.

8. Subjects of reproductive potential must agree to use acceptable birth control methods

Exclusion Criteria:

1. Active invasive cancer other than the study-targeted malignancy.

2. Evidence of active hepatitis B or hepatitis C. The following would not qualify as an

active infection, thus would not exclude the subject from participating:

1. Positive HBV serology with undetectable viral load and ongoing antiviral prophylaxis for potential HBV reactivation.

2. Positive HCV serology with quantitative PCR for plasma HCV RNA below the lower limit of detection, with or without concurrent antiviral HCV treatment.

3. Patients with ongoing or active infection.

4. Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to = 10 mg/day of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded.

5. Planned concurrent treatment with systemic high dose corticosteroids. Patients may be on a stable low dose of steroids (= 10mg daily equivalent of prednisone). Use of inhaled or topical steroids is allowable.

6. History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).

7. Pregnant or breastfeeding women.

8. Any clinically significant pericardial effusion, Class II-IV cardiovascular disability according to the New York Heart Association Classification or other cardiovascular condition that would preclude assessment of mesothelin induced pericarditis or that may worsen as a result of toxicities expected for this study. This determination will be made by a cardiologist if cardiac issues are suspected.

9. Patients with significant lung disease as follows:

1. Patients with radiographic evidence of greater than lobar lymphangitic pulmonary involvement, greater than lobar bronchial wall thickening suggestive of peribronchial lymphatic disease extension, and/or evidence of extensive bilateral parenchymal metastatic burden.

2. Patients with radiographic and/or clinical evidence of active radiation pneumonitis.

3. Patients with radiographic evidence of underlying interstitial lung disease, including evidence of unresolved drug toxicity from any agent (e.g. chemotherapy, targeted agents, amiodarone, nitrofurantoin, etc).

10. Patients with active central nervous system (CNS) involvement. Screening for this (e.g. lumbar puncture, brain MRI, etc) is not required unless the patient is symptomatic and/or radiographic findings are present.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• huCART-meso cells
Autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor M5 scFv fused to the 4-1BB and CD3? signaling domains

Device:
• Mesothelin Expression Testing
Laboratory Developed Test

Locations

Country	Name	City	State
United States	University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of treatment-limiting toxicities (TLTs)		90 days
Primary	Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0.		15 years
Secondary	Proportion of manufacturing product that do not meet the release criteria.		60 days
Secondary	Proportion of the products that meet the target dose.		60 days
Secondary	Proportion of enrolled subjects that receive study treatment.		60 days
Secondary	Proportion of eligible subjects that receive study treatment		60 days
Secondary	Proportion of subjects for which standard of care treatment is not impacted due to CAR T cell related toxicity.		90 days
Secondary	Kinetics of expansion and persistence of infused cells by flow cytometry.		90 days
Secondary	Kinetics of expansion and persistence of infused cells by quantitative PCR.		90 days